VP3: Vancouver Primary Prevention Program (Anxiety Disorders Prevention in School Children)
Launched by UNIVERSITY OF BRITISH COLUMBIA · Oct 31, 2005
Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Children enrolled in school between the ages of 7 and 13 who display anxiety symptoms.
- • 1. Anxiety disorder symptoms (identified by a score of 56 or higher on the MASC; and teacher report, and /or parent recommendation) as the primary presenting problem. An enrolled child must have at least 2 of these criterions.
- • 2. Fluency in English.
- • 3. Parent willingness to sign consent form and to complete required assessments.
- • 4. Student willingness to participate (child assent) in 10-week affective education program and completion of required assessments.
- Exclusion Criteria:
About University Of British Columbia
The University of British Columbia (UBC) is a leading research institution located in Vancouver, Canada, renowned for its commitment to advancing health sciences through innovative research and education. As a prominent clinical trial sponsor, UBC leverages its interdisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical studies aimed at improving patient outcomes across various medical fields. The university fosters collaborations with healthcare professionals, industry partners, and community stakeholders to translate research findings into practical applications, thereby contributing to the global advancement of medicine and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vancouver, British Columbia, Canada
Patients applied
Trial Officials
Lynn Miller, PhD, R.Psych.
Principal Investigator
University of British Columbia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials